Genentech, a member of the Roche Group, is a pioneering biotechnology company headquartered in South San Francisco, US. Founded in 1976, Genentech has been at the forefront of the biotechnology industry, focusing on the development of innovative medicines for serious medical conditions. The company is renowned for its contributions to oncology, immunology, and neuroscience, with a portfolio that includes groundbreaking therapies such as Herceptin and Avastin. With a commitment to research and development, Genentech has achieved numerous milestones, including the first-ever recombinant DNA product approved by the FDA. Its unique approach to drug development, combining cutting-edge science with a patient-centric philosophy, has solidified its position as a leader in the biopharmaceutical market. Genentech continues to set benchmarks in the industry, driving advancements that improve patient outcomes globally.
How does Genentech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Genentech's score of 40 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2019, Genentech, headquartered in the US, reported total carbon emissions of approximately 140,550,000 kg CO2e, which includes Scope 1 emissions of about 64,980,000 kg CO2e and Scope 2 emissions of approximately 63,436,000 kg CO2e. The company also disclosed Scope 3 emissions, which totalled around 73,904,000 kg CO2e, comprising business travel and employee commuting. Genentech's emissions data is cascaded from its parent company, Roche Holding AG, indicating a corporate family relationship. However, there are currently no specific reduction targets or climate pledges documented for Genentech, nor are there any initiatives reported under the Science Based Targets initiative (SBTi) or other climate frameworks. The company has shown a commitment to sustainability through its emissions reporting, but further details on specific reduction initiatives or targets are not available. As part of the pharmaceutical industry, Genentech is positioned within a sector increasingly focused on reducing carbon footprints and enhancing environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2004 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 54,533,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 21,308,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genentech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.